The evolution of modern respiratory care for preterm infants

The Lancet

Volumn 389, Issue 10079, 2017, Pages 1649-1659

  Owen, Louise S ^a,b,c   Manley, Brett J ^a,b   Davis, Peter G ^a,b,c   Doyle, Lex W ^a,b,c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; OXYGEN; SURFACTANT;

ARTIFICIAL VENTILATION; ASSISTED VENTILATION; BIRTH; CORTICOSTEROID THERAPY; DRUG USE; HUMAN; INTERMITTENT POSITIVE PRESSURE VENTILATION; LUNG DYSPLASIA; MORBIDITY; MORTALITY; NASAL HIGH FLOW THERAPY; NASAL INTERMITTENT POSITIVE PRESSURE VENTILATION; NEONATOLOGY; NEWBORN CARE; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; OXYGEN SATURATION; OXYGEN THERAPY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY CARE; REVIEW; RISK FACTOR; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN;

HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RESPIRATORY THERAPY;

EID: 85018462473     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30312-4     Document Type: Review

References (108)

1. 1 Kitchen, WH, Ryan, MM, Rickards, A, et al. Changing outcome over 13 years of very low birthweight infants. Semin Perinatol 6 (1982), 373–389.
2. 2 Liggins, GC, Howie, RN, A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50 (1972), 515–525.
3. 3 Gultom, E, Doyle, LW, Davis, P, Dharmalingam, A, Bowman, E, Changes over time in attitudes to treatment and survival rates for extremely preterm infants (23–27 weeks' gestational age). Aust N Z J Obstet Gynaecol 37 (1997), 56–58.
4. 4 Richard, D, Poets, CF, Neale, S, Stebbens, VA, Alexander, JR, Southall, DP, Arterial oxygen saturation in preterm neonates without respiratory failure. J Pediatr 123 (1993), 963–968.
5. 5 Tin, W, Milligan, DW, Pennefather, P, Hey, E, Pulse oximetry, severe retinopathy, and outcome at one year in babies of less than 28 weeks gestation. Arch Dis Child Fetal Neonatal Ed 84 (2001), F106–F110.
6. 6 The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105 (2000), 295–310.
7. 7 Askie, LM, Henderson-Smart, DJ, Irwig, L, Simpson, JM, Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 349 (2003), 959–967.
8. 8 Askie, LM, Brocklehurst, P, Darlow, BA, Finer, N, Schmidt, B, Tarnow-Mordi, W, NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. BMC Pediatr, 11, 2011, 6.
9. 9 Carlo, WA, Finer, NN, Walsh, MC, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 362 (2010), 1959–1969.
10. 10 Vaucher, YE, Peralta-Carcelen, M, Finer, NN, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 367 (2012), 2495–2504.
11. 11 Darlow, BA, Marschner, SL, Donoghoe, M, et al. Randomized controlled trial of oxygen saturation targets in very preterm infants: two year outcomes. J Pediatr 165 (2014), 30–35 e2.
12. 12 Stenson, BJ, Tarnow-Mordi, WO, Darlow, BA, et al. Oxygen saturation and outcomes in preterm infants. N Engl J Med 368 (2013), 2094–2104.
13. 13 Tarnow-Mordi, W, Stenson, B, Kirby, A, et al. Outcomes of two trials of oxygen-saturation targets in preterm infants. N Engl J Med 374 (2016), 749–760.
14. 14 Schmidt, B, Whyte, RK, Asztalos, EV, et al. Effects of targeting higher vs lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. JAMA 309 (2013), 2111–2120.
15. 15 Stenson, BJ, Oxygen saturation targets for extremely preterm infants after the NeOProM trials. Neonatology 109 (2016), 352–358.
16. 16 AAP Committee on Fetus and Newborn and ACOG Committee on Obstetric Practice. Guidelines for perinatal care, 2012, American Academy of Pediatrics, Elk Grove Village, IL.
17. 17 Sweet, DG, Carnielli, V, Greisen, G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants—2013 update. Neonatology 103 (2013), 353–368.
18. 18 van Zanten, HA, Tan, RN, van den Hoogen, A, Lopriore, E, te Pas, AB, Compliance in oxygen saturation targeting in preterm infants: a systematic review. Eur J Pediatr 174 (2015), 1561–1572.
19. 19 Hummler, H, Fuchs, H, Schmid, M, Automated adjustments of inspired fraction of oxygen to avoid hypoxemia and hyperoxemia in neonates—a systematic review on clinical studies. Klin Padiatr 226 (2014), 204–210.
20. 20 Sood, BG, McLaughlin, K, Cortez, J, Near-infrared spectroscopy: applications in neonates. Semin Fetal Neonatal Med 20 (2015), 164–172.
21. 21 Watkin, SL, Spencer, SA, Dimmock, PW, Wickramasinghe, YA, Rolfe, P, A comparison of pulse oximetry and near infrared spectroscopy (NIRS) in the detection of hypoxaemia occurring with pauses in nasal airflow in neonates. J Clin Monit Comput 15 (1999), 441–447.
22. 22 Avery, ME, Mead, J, Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child 97 (1959), 517–523.
23. 23 Klaus, MH, Clements, JA, Havel, RJ, Composition of surface-active material isolated from beef lung. Proc Natl Acad Sci USA 47 (1961), 1858–1859.
24. 24 Robillard, E, Alarie, Y, Dagenais-Perusse, P, Baril, E, Guilbeault, A, Microaerosol administration of synthetic beta-gamma-dipalmitoyl-L-alpha-lecithin in the respiratory distress syndome: a preliminary report. Can Med Assoc J 90 (1964), 55–57.
25. 25 Fujiwara, T, Maeta, H, Chida, S, Morita, T, Watabe, Y, Abe, T, Artificial surfactant therapy in hyaline-membrane disease. Lancet 1 (1980), 55–59.
26. 26 Soll, RF, Ozek, E, Prophylactic animal derived surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev, 4, 1997 CD000511.
27. 27 Soll, RF, Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev, 2, 1998 CD001149.
28. 28 Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics 82 (1988), 683–691.
29. 29 Seger, N, Soll, R, Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev, 2, 2009 CD007836.
30. 30 Soll, R, Ozek, E, Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev, 1, 2009 CD000141.
31. 31 Ardell, S, Pfister, RH, Soll, R, Animal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev, 5, 2015 CD000144.
32. 32 Singh, N, Halliday, HL, Stevens, TP, Suresh, G, Soll, R, Rojas-Reyes, MX, Comparison of animal-derived surfactants for the prevention and treatment of respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev, 12, 2015 CD010249.
33. 33 Pfister, RH, Soll, RF, Wiswell, T, Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev, 4, 2007 CD006069.
34. 34 Second working group of the British Association of Perinatal Medicine. Guidelines for good practice in the management of neonatal respiratory distress syndrome. http://www.bapm.org/publications/documents/guidelines/rds.pdf, 1999 (accessed June 10, 2016).
35. 35 Rojas-Reyes, MX, Morley, CJ, Soll, R, Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev, 3, 2012 CD000510.
36. 36 Morley, CJ, Davis, PG, Doyle, LW, Brion, LP, Hascoet, JM, Carlin, JB, Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 358 (2008), 700–708.
37. 37 Stevens, TP, Harrington, EW, Blennow, M, Soll, RF, Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev, 4, 2007 CD003063.
38. 38 Kattwinkel, J, Robinson, M, Bloom, BT, Delmore, P, Ferguson, JE, Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 24 (2004), 360–365.
39. 39 Sood, BG, Aerosolized surfactant in neonatal RDS. https://clinicaltrials.gov/ct2/show/NCT02294630?term=surfactant+aerosolized&rank=1, 2014 (accessed June 10, 2016).
40. 40 Pinheiro, JM, Santana-Rivas, Q, Pezzano, C, Randomized trial of laryngeal mask airway versus endotracheal intubation for surfactant delivery. J Perinatol 36 (2016), 196–201.
41. 41 Gopel, W, Kribs, A, Ziegler, A, et al. Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 378 (2011), 1627–1634.
42. 42 Kanmaz, HG, Erdeve, O, Canpolat, FE, Mutlu, B, Dilmen, U, Surfactant administration via thin catheter during spontaneous breathing: randomized controlled trial. Pediatrics 131 (2013), e502–e509.
43. 43 Greenough, A, Dimitriou, G, Prendergast, M, Milner, AD, Synchronized mechanical ventilation for respiratory support in newborn infants. Cochrane Database Syst Rev, 1, 2008 CD000456.
44. 44 Wheeler, K, Klingenberg, C, McCallion, N, Morley, CJ, Davis, PG, Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev, 11, 2010 CD003666.
45. 45 Klingenberg, C, Wheeler, KI, Owen, LS, Kaaresen, PI, Davis, PG, An international survey of volume-targeted neonatal ventilation. Arch Dis Child Fetal Neonatal Ed 96 (2011), F146–F148.
46. 46 Stein, H, Alosh, H, Ethington, P, White, DB, Prospective crossover comparison between NAVA and pressure control ventilation in premature neonates less than 1500 grams. J Perinatol 33 (2013), 452–456.
47. 47 Cools, F, Offringa, M, Askie, LM, Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev, 3, 2015 CD000104.
48. 48 Bhuta, T, Henderson-Smart, DJ, Elective high frequency jet ventilation versus conventional ventilation for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev, 2, 2000 CD000328.
49. 49 Rojas-Reyes, MX, Orrego-Rojas, PA, Rescue high-frequency jet ventilation versus conventional ventilation for severe pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev, 10, 2015 CD000437.
50. 50 Gregory, GA, Kitterman, JA, Phibbs, RH, Tooley, WH, Hamilton, WK, Treatment of the idiopathic respiratory-distress syndrome with continuous positive airway pressure. N Engl J Med 284 (1971), 1333–1340.
51. 51 De Paoli, AG, Davis, PG, Faber, B, Morley, CJ, Devices and pressure sources for administration of nasal continuous positive airway pressure (NCPAP) in preterm neonates. Cochrane Database Syst Rev, 1, 2008 CD002977.
52. 52 Davis, PG, Henderson-Smart, DJ, Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. Cochrane Database Syst Rev, 2, 2003 CD000143.
53. 53 De Luca, D, Dell'Orto, V, Non-invasive high-frequency oscillatory ventilation in neonates: review of physiology, biology and clinical data. Arch Dis Child Fetal Neonatal Ed, 2016, 10.1136/archdischild-2016-310664 published online June 28.
54. 54 Roberts, CT, Davis, PG, Owen, LS, Neonatal non-invasive respiratory support: synchronised NIPPV, non-synchronised NIPPV or bi-level CPAP: what is the evidence in 2013?. Neonatology 104 (2013), 203–209.
55. 55 Lemyre, B, Davis, PG, De Paoli, AG, Kirpalani, H, Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev, 9, 2014 CD003212.
56. 56 Manley, BJ, Owen, LS, High-flow nasal cannula: mechanisms, evidence and recommendations. Semin Fetal Neonatal Med 21 (2016), 139–145.
57. 57 Wilkinson, D, Andersen, C, O'Donnell, CP, De Paoli, AG, Manley, BJ, High flow nasal cannula for respiratory support in preterm infants. Cochrane Database Syst Rev, 2, 2016 CD006405.
58. 58 Avery, ME, Tooley, WH, Keller, JB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 79 (1987), 26–30.
59. 59 Jacobsen, T, Gronvall, J, Petersen, S, Andersen, GE, “Minitouch” treatment of very low-birth-weight infants. Acta Paediatr 82 (1993), 934–938.
60. 60 Schmolzer, GM, Kumar, M, Pichler, G, Aziz, K, O'Reilly, M, Cheung, PY, Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ, 347, 2013, f5980.
61. 61 Tang, S, Zhao, J, Shen, J, Hu, Z, Shi, Y, Nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure in neonates: a systematic review and meta-analysis. Indian Pediatr 50 (2013), 371–376.
62. 62 Roberts, CT, Owen, LS, Manley, BJ, et al. Nasal high-flow therapy for primary respiratory support in preterm infants. N Engl J Med 375 (2016), 1142–1151.
63. 63 Baden, M, Bauer, CR, Colle, E, Klein, G, Taeusch, HW Jr, Stern, L, A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 50 (1972), 526–534.
64. 64 Fitzhardinge, PM, Eisen, A, Lejtenyi, C, Metrakos, K, Ramsay, M, Sequelae of early steroid administration to the newborn infant. Pediatrics 53 (1974), 877–883.
65. 65 Taeusch, HW Jr, Wang, NS, Baden, N, Bauer, CR, Stern, L, A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome: II. Pathology. Pediatrics 52 (1973), 850–854.
66. 66 Ewerbeck, H, Helwig, H, Reynolds, JW, Provenzano, RW, Treatment of idiopathic respiratory distress with large doses of corticoids. Pediatrics 49 (1972), 467–468.
67. 67 Mammel, MC, Green, TP, Johnson, DE, Thompson, TR, Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet 1 (1983), 1356–1358.
68. 68 Hack, M, Fanaroff, AA, Outcomes of children of extremely low birthweight and gestational age in the 1990's. Early Hum Dev 53 (1999), 193–218.
69. 69 Yeh, TF, Lin, YJ, Huang, CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics, 101, 1998, E7.
70. 70 Halliday, HL, Ehrenkranz, RA, Doyle, LW, Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev, 1, 2003 CD001146.
71. 71 Halliday, HL, Ehrenkranz, RA, Doyle, LW, Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev, 1, 2003 CD001144.
72. 72 Halliday, H, Guidelines on neonatal steroids. Prenat Neonat Med 6 (2001), 371–373.
73. 73 Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109 (2002), 330–338.
74. 74 Walsh, MC, Yao, Q, Horbar, JD, Carpenter, JH, Lee, SK, Ohlsson, A, Changes in the use of postnatal steroids for bronchopulmonary dysplasia in 3 large neonatal networks. Pediatrics 118 (2006), e1328–e1335.
75. 75 Yoder, BA, Harrison, M, Clark, RH, Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 124 (2009), 673–679.
76. 76 Doyle, LW, Halliday, HL, Ehrenkranz, RA, Davis, PG, Sinclair, JC, An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. J Pediatr 165 (2014), 1258–1260.
77. 77 Doyle, LW, Ehrenkranz, RA, Halliday, HL, Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev, 5, 2014 CD001146.
78. 78 Doyle, LW, Ehrenkranz, RA, Halliday, HL, Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev, 5, 2014 CD001145.
79. 79 Onland, W, Offringa, M, De Jaegere, AP, van Kaam, AH, Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics 123 (2009), 367–377.
80. 80 Doyle, LW, Davis, PG, Morley, CJ, McPhee, A, Carlin, JB, Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics 117 (2006), 75–83.
81. 81 Doyle, LW, Ehrenkranz, RA, Halliday, HL, Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology 98 (2010), 111–117.
82. 82 Baud, O, Maury, L, Lebail, F, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 387 (2016), 1827–1836.
83. 83 Shah, VS, Ohlsson, A, Halliday, HL, Dunn, M, Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev, 5, 2012 CD001969.
84. 84 Onland, W, Offringa, M, van Kaam, A, Late (>/= 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev, 4, 2012 CD002311.
85. 85 Shah, SS, Ohlsson, A, Halliday, HL, Shah, VS, Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev, 5, 2012 CD002058.
86. 86 Shah, SS, Ohlsson, A, Halliday, HL, Shah, VS, Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev, 5, 2012 CD002057.
87. 87 Bassler, D, Plavka, R, Shinwell, ES, et al. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med 373 (2015), 1497–1506.
88. 88 Yeh, TF, Chen, CM, Wu, SY, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med 193 (2016), 86–95.
89. 89 Stoll, BJ, Hansen, NI, Bell, EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012. JAMA 314 (2015), 1039–1051.
90. 90 Wilson, MG, Mikity, VG, A new form of respiratory disease in premature infants. AMA J Dis Child 99 (1960), 489–499.
91. 91 Jobe, AJ, The new BPD: an arrest of lung development. Pediatr Res 46 (1999), 641–643.
92. 92 Thibeault, DW, Mabry, SM, Norberg, M, Truog, WE, Ekekezie, II, Lung microvascular adaptation in infants with chronic lung disease. Biol Neonate 85 (2004), 273–282.
93. 93 Kotecha, SJ, Edwards, MO, Watkins, WJ, et al. Effect of preterm birth on later FEV1: a systematic review and meta-analysis. Thorax 68 (2013), 760–766.
94. 94 Ehrenkranz, RA, Walsh, MC, Vohr, BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 116 (2005), 1353–1360.
95. 95 Poindexter, BB, Feng, R, Schmidt, B, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the Prematurity and Respiratory Outcomes Program. Ann Am Thorac Soc 12 (2015), 1822–1830.
96. 96 Parad, RB, Davis, JM, Lo, J, et al. Prediction of respiratory outcome in extremely low gestational age infants. Neonatology 107 (2015), 241–248.
97. 97 Roberts, G, Cheong, JL, Long-term growth and general health for the tiniest or most immature infants. Semin Fetal Neonatal Med 19 (2014), 118–124.
98. 98 Doyle, LW, Faber, B, Callanan, C, Freezer, N, Ford, GW, Davis, NM, Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 118 (2006), 108–113.
99. 99 Gibson, AM, Doyle, LW, Respiratory outcomes for the tiniest or most immature infants. Semin Fetal Neonatal Med 19 (2014), 105–111.
100. 100 Kajantie, E, Hovi, P, Is very preterm birth a risk factor for adult cardiometabolic disease?. Semin Fetal Neonatal Med 19 (2014), 112–117.
101. 101 Mourani, PM, Abman, SH, Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. Curr Opin Pediatr 25 (2013), 329–337.
102. 102 Doyle, LW, Anderson, PJ, Long-term outcomes of bronchopulmonary dysplasia. Semin Fetal Neonatal Med 14 (2009), 391–395.
103. 103 Schmidt, B, Roberts, RS, Davis, P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med 354 (2006), 2112–2121.
104. 104 Bell, EF, Acarregui, MJ, Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev, 12, 2014 CD000503.
105. 105 Taylor, S, Rehan, VK, Anti-inflammatory agents for the prevention of bronchopulmonary dysplasia. Bhandari, V, (eds.) Bronchopulmonary dysplasia, 1st edn., 2016, Springer International Publishing, Switzerland, 325–344.
106. 106 Chang, YS, Oh, W, Choi, SJ, et al. Human umbilical cord blood-derived mesenchymal stem cells attenuate hyperoxia-induced lung injury in neonatal rats. Cell Transplant 18 (2009), 869–886.
107. 107 Chang, YS, Ahn, SY, Yoo, HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr 164 (2014), 966–972 e6.
108. 108 ClinicalTrials.gov. Efficacy and safety evaluation of pneumostem versus a control group for treatment of BPD in premature infants. 2015 https://clinicaltrials.gov/ct2/show/NCT01828957?term=mesenchymal+stem+cell+infant+randomized&rank=1 (accessed June 10, 2016).